institutional equity research nestle india (nest in...

INSTITUTIONAL EQUITY RESEARCH

Page | 1 | PHILLIPCAPITAL INDIA RESEARCH Please see penultimate page for additional important disclosures. PhillipCapital (India) Private Limited. (“PHILLIPCAP”) is a foreign broker-dealer unregistered in the USA. PHILLIPCAP research is prepared by research analysts who are not registered in the USA. PHILLIPCAP research is distributed in the USA pursuant to Rule 15a-6 of the Securities Exchange Act of 1934 solely by Rosenblatt Securities Inc, an SEC registered and FINRA-member broker-dealer.

Nestle India (NEST IN)

Higher ad spends probably weighed on performance

INDIA | FMCG | Quarterly Update

14 February 2019

Top takeaways from Q4CY18 Nestle Q4CY18 results were below our estimates due to subdued growth in exports

business, tapering off of gross margin tailwinds and probably higher ad spends. Domestic business continues to remain solid (12% growth YoY) on back of 1) continued build –up in Maggi portfolio 2) traction on new launches and 3) management “WIMI” (distribution revamp) strategy starting to bear initial results. Exports business remained flat yoy after seeing four quarters of steady performance due to lower sales to Bangladesh and UAE

Gross margin remained flat yoy as tailwinds turned into headwinds on commodity front. We believe so far, Nestle was able to utilize benefits of lower input costs on investing behind brand building. However, other expenses shot up 23% yoy in 4QCY18 probably due to higher ad spend. We are not sure as to what quantum of other expenses went up due to higher ad spends

Wait and watch till next quarter - We believe it is difficult for sell side analyst to truly gauge current quarter performance ; since if significant part of increase in other expenses is due to ad spends; then it is very good in long term; although in short term; it might affect operating performance. We also need to assess as to why ad spends have shot up – 1) increased competition in core categories or 2) incubation of new categories. We would closely monitor next quarter performance to meaningfully change our stance / estimates

Continue to maintain the faith ; Remain bullish We maintain Nestle (along with HUL) as Top pick within the large cap space as we believe Nestle has all right ingredients in place – 1) management focus on volume driven growth vs prior management obsession with profitability only 2) premiumization in core categories (for e.g launching different variants of Maggi) 3) entry into newer categories (nutritional supplements category, breakfast cereals, yogurt, canned beverages etc) and 4) improving distribution efficiency. We maintain BUY with TP of 12,000 (50x March -21) New launches made in past two years

Month Product Category

Dec-18 Nestle Everyday Chai Life- Desi Masala, Saffron & Cardamon, Ginger and Lemon grass

Beverages

Nov-18 Nestle Les Recettes De L'Atelier- 4 variant Chocolates Sep-18 Maggi Dip & Spread Dip & Spread Jul-18 NESPLUS -Kokos, Choco-Burst Fillows, Strawberry Burst Fillows, Nutty Honey Breakfast Cereals

Mar-18 Munch - Crunch-O-Nuts Chocolates Feb-18 Kitkat - Strawberry Duo Chocolates Sep-17 Kit Kat – Dessert Delight Chocolates Aug-17 Maggi Nutri-Licious noodle Noodles

Iron-fortified Maggi Noodles – to make maggi healthier ’ Noodles

Nestle A+ Grekyo (Blueberry Greek Yogurt/ Greek Style Curd) Yogurt

May-17 Maggi Masala (Amritsari Achari, Mumbaiya Chatak, Super Chennai, Bengali Jhaal)

Noodles

Mar-17 Milo Ready to Drink Beverages Oct-16 Nescafe Ready to Drink Beverages

Nestle A+ Pro-Grow Milk & Nutrition

Maggi CUPPA Masala/Chilly Chow/ Hot Heads Noodles

Maggi No Onion No Garlic Masala Noodles

BUY (Maintain) CMP RS 10611 TARGET RS 12,000 (13%) COMPANY DATA

O/S SHARES (MN) : 96

MARKET CAP (RSBN) : 1025

MARKET CAP (USDBN) : 14

52 - WK HI/LO (RS) : 11777/7187

LIQUIDITY 3M (USDMN) : 12.5

PAR VALUE (RS) : 10

SHARE HOLDING PATTERN, %

Dec 18 Sep 18 Jun 18

PROMOTERS : 62.8 62.8 62.8

FII / NRI : 12.6 12.3 12.4

FI / MF : 7.3 7.9 7.9

NON PRO : 5.0 5.0 5.0

PUBLIC & OTHERS : 12.3 12.0 12.0

KEY FINANCIALS

Rs mn CY19E CY20E CY21E

Net Sales 1,26,945 1,42,737 1,60,907

EBIDTA 30,895 35,683 40,560

Net Profit 19,120 22,317 25,670

EPS, Rs 198.3 231.5 266.3

PER, x 53.5 45.8 39.8

EV/EBIDTA, x 31.6 27.1 23.5

ROE, % 24.6 22.0 19.7

Debt/Equity (%) 46.0 48.0 49.6

CHANGE IN ESTIMATES

__Revised Est. __ __% Revision__

Rs bn CY19E CY20E CY19E CY20E

Revenue 1,26,945 1,42,737 0% 0%

EBITDA 30,895 35,683 -3% -2%

Core PAT 19,120 22,317 -1% -2%

EPS (Rs) 198 231 -1% -2% Vishal Gutka Preeyam Tolia

(Rs mn) 4QCY18 4QCY17 yoy 3QCY18

qoq PC yoy growth estimates %

Comments

Net Sales 28,788 25,896 11.2 29,220 (1.5) 13.1

EBITDA 5,575 5,639 (1.1) 7,252 (23.1) 20.0

EBITDA margin (%) 19.4 21.8 -241 bps 24.8 -545 bps 132 bps

PAT 3,418 3,118 9.6 4,461 (23.4) 27.5

Page | 2 | PHILLIPCAPITAL INDIA RESEARCH

NESTLE INDIA QUARTERLY UPDATE

Financial snapshot

Rs mn 4QCY17 4QCY18 % YoY Comments

Volume (%) 18.0 -

Net Sales 25,896 28,788 11.2% Domestic business continues to remain solid up 12% yoy

Other operating income 118 184 56.0%

Total Expenses (20,375) (23,398) 14.8%

EBITDA 5,639 5,575 -1.1%

EBITDA margin (%) 21.8 19.4 -241bps

Interest (234) (252) 7.6%

Depreciation (1,142) (854) -25.3%

Other income 511 752 47.2%

PBT 4,774 5,222 9.4%

Tax (1,656) (1,804) 9.0%

Tax rate (%) 34.7 34.6 -13bps

Pre-exceptional PAT 3,118 3,418 9.6%

Net margin (%) 12.0 11.9 -17bps

Exceptional Items - -

Reported PAT 3,118 3,418 9.6%

No of shares 96 96 0.0%

EPS (Rs) 32.3 35.4 9.6%

EPS 32.3 35.4 9.6%

Cost Details 4QCY17 4QCY18 % YoY

Raw Materials 10,693 11,894 11.2%

As % of Sales 41.3 41.3 3bps

Staff costs 2,607 2,799 7.3%

As % of Sales 10.1 9.7 -35bps

Other expenses 7,075 8,705 23.0%

As % of Sales 27.3 30.2 291bps

Gross profit 15,203.8 16,894.0 11.1% Gross margin remained flat yoy as tailwinds turned into headwinds on commodity

front Gross margin 58.71 58.68 -3bps

Source: Company, PhillipCapital India Research



All key commodities (except Coffee) seems to be in upward spiral

Units Dec-18 Dec-17 yoy %

Wheat INR/qt 2,055 1,815 13.2 Gur & Sugar INR/qt 3,460 3,953 (12.5) Cocoa INR/mt 1,56,049 1,34,807 15.8 Coffee robusta INR/mt 1,15,714 1,20,148 (3.7) Skimmed Milk powder INR/mt 1,37,655 1,12,556 22.3

Two-year forward P/E Band EV/EBITDA band

Source: PhillipCapital India Research Estimate

15x

30x

45x

60x

0

2000

4000

6000

8000

10000

12000

14000

16000

18000 Rs P/E

10x

20x

30x

40x

0

200000

400000

600000

800000

1000000

1200000

1400000

1600000

1800000 Rs mn EV/EBITDA



Financials

Income Statement Y/E Mar, Rs mn CY18 CY19E CY20E CY21E

Net sales 1,12,162 1,26,945 1,42,737 1,60,907 Growth, % 13 13 12 13 Other operating income 760 814 871 932 Total income 1,12,923 1,27,758 1,43,607 1,61,838 Raw material expenses -45,902 -51,870 -57,575 -64,484 Employee expenses -11,242 -12,647 -14,228 -16,006 Other Operating expenses -29,492 -32,347 -36,122 -40,788 EBITDA (Core) 26,287 30,895 35,683 40,560 Growth, % 23.2 17.5 15.5 13.7 Margin, % 23.4 24.3 25.0 25.2 Depreciation -3,468 -3,933 -4,244 -4,464 EBIT 22,820 26,962 31,439 36,096 Growth, % 30.1 18.2 16.6 14.8 Margin, % 20.3 21.2 22.0 22.4 Interest paid -1,120 -1,231 -1,355 -1,490 Other Income 2,589 2,978 3,424 3,938 Non-recurring Items 0 0 0 0 Pre-tax profit 24,290 28,708 33,508 38,543 Tax provided -8,220 -9,589 -11,192 -12,873 Profit after tax 16,069 19,120 22,317 25,670 Net Profit (adjusted) 16,069 19,120 22,317 25,670 Unadj. shares (m) 96 96 96 96 Wtd avg shares (m) 96 96 96 96

Balance Sheet Y/E Mar, Rs mn CY18E CY19E CY20E CY21E

Cash & bank 21,468 31,496 42,367 54,471 Marketable securities at cost 13,936 13,936 13,936 13,936 Debtors 922 1,043 1,173 1,323 Inventory 10,141 11,477 12,905 14,548 Loans & advances 752 752 752 752 Other current assets 661 661 661 661 Total current assets 47,880 59,365 71,794 85,690 Investments 5,853 5,853 5,853 5,853 Gross fixed assets 35,584 37,584 39,584 41,584 Less: Depreciation -10,890 -14,823 -19,067 -23,531 Add: Capital WIP 942 942 942 942 Net fixed assets 25,636 23,703 21,459 18,995 Non-current assets 832 832 832 832 Total assets 80,201 89,753 99,938 1,11,370 Current liabilities 15,883 17,422 19,066 20,958 Provisions 25,813 29,215 32,849 37,031 Total current liabilities 41,696 46,637 51,915 57,989 Non-current liabilities 1,577 1,577 1,577 1,577 Total liabilities 43,273 48,214 53,492 59,566 Paid-up capital 964 964 964 964 Reserves & surplus 35,963 40,575 45,482 50,840 Shareholders’ equity 36,928 41,539 46,446 51,804 Total equity & liabilities 80,201 89,753 99,938 1,11,370

Source: Company, PhillipCapital India Research Estimates

Cash Flow

CY18E CY19E CY20E CY21E

Pre-tax profit 24,290 28,708 33,508 38,543 Depreciation 3,468 3,933 4,244 4,464 Chg in working capital 2,705 3,483 3,721 4,281 Total tax paid -8,220 -9,589 -11,192 -12,873 Other operating activities 0 0 0 0 Cash flow from operating activities 22,242 26,536 30,282 34,415 Capital expenditure -2,000 -2,000 -2,000 -2,000 Chg in investments 0 0 0 0 Chg in marketable securities 0 0 0 0 Other investing activities 0 0 0 0 Cash flow from investing activities -2,000 -2,000 -2,000 -2,000 Free cash flow 20,242 24,536 28,282 32,415 Equity raised/(repaid) 0 0 0 0 Debt raised/(repaid) 0 0 0 0 Dividend (incl. tax) -13,348 -14,508 -17,410 -20,311 Other financing activities 0 0 0 0 Cash flow from financing activities -13,348 -14,508 -17,410 -20,311 Net chg in cash 6,894 10,027 10,872 12,104

Valuation Ratios

CY18E CY19E CY20E CY21E

Per Share data

EPS (INR) 166.7 198.3 231.5 266.3 Growth, % 31.2 19.0 16.7 15.0 Book NAV/share (INR) 383.1 430.9 481.8 537.4 FDEPS (INR) 166.7 198.3 231.5 266.3 CEPS (INR) 202.7 239.1 275.5 312.6 CFPS (INR) 203.9 244.4 278.6 316.2 DPS (INR) 115.0 125.0 150.0 175.0 Return ratios

Return on assets (%) 22.3 23.9 25.0 25.7 Return on equity (%) 43.5 46.0 48.0 49.6 Return on capital employed (%) 27.9 29.8 30.9 31.7 Turnover ratios

Asset turnover (x) 4.9 6.0 7.5 9.7 Sales/Total assets (x) 1.5 1.5 1.5 1.5 Sales/Net FA (x) 4.3 5.1 6.3 8.0 Receivable days 3.0 3.0 3.0 3.0 Inventory days 33.0 33.0 33.0 33.0 Payable days 45.3 45.9 46.3 46.4 Working capital days (11.1) (10.0) (9.1) (8.3) Liquidity ratios Current ratio (x) 3.0 3.4 3.8 4.1 Quick ratio (x) 2.4 2.7 3.1 3.4 Interest cover (x) 20.4 21.9 23.2 24.2 Total debt/Equity (%) 1.0 0.8 0.8 0.7 Net debt/Equity (%) (57.2) (75.0) (90.5) (104.5) Valuation PER (x) 63.7 53.5 45.8 39.8 PEG (x) - y-o-y growth 2.0 2.8 2.7 2.7 Price/Book (x) 27.7 24.6 22.0 19.7 EV/Net sales (x) 8.8 7.7 6.8 5.9 EV/EBITDA (x) 37.6 31.6 27.1 23.5 EV/EBIT (x) 43.3 36.3 30.8 26.5



Stock Price, Price Target and Rating History

Rating Methodology We rate stock on absolute return basis. Our target price for the stocks has an investment horizon of one year.

Rating Criteria Definition

BUY >= +15% Target price is equal to or more than 15% of current market price

NEUTRAL -15% > to < +15% Target price is less than +15% but more than -15%

SELL <= -15% Target price is less than or equal to -15%.

Disclosures and Disclaimers PhillipCapital (India) Pvt. Ltd. has three independent equity research groups: Institutional Equities, Institutional Equity Derivatives, and Private Client Group. This report has been prepared by Institutional Equities Group. The views and opinions expressed in this document may, may not match, or may be contrary at times with the views, estimates, rating, and target price of the other equity research groups of PhillipCapital (India) Pvt. Ltd.

This report is issued by PhillipCapital (India) Pvt. Ltd., which is regulated by the SEBI. PhillipCapital (India) Pvt. Ltd. is a subsidiary of Phillip (Mauritius) Pvt. Ltd. References to "PCIPL" in this report shall mean PhillipCapital (India) Pvt. Ltd unless otherwise stated. This report is prepared and distributed by PCIPL for information purposes only, and neither the information contained herein, nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security, investment, or derivatives. The information and opinions contained in the report were considered by PCIPL to be valid when published. The report also contains information provided to PCIPL by third parties. The source of such information will usually be disclosed in the report. Whilst PCIPL has taken all reasonable steps to ensure that this information is correct, PCIPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and PCIPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

This report does not regard the specific investment objectives, financial situation, and the particular needs of any specific person who may receive this report. Investors must undertake independent analysis with their own legal, tax, and financial advisors and reach their own conclusions regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realised. Under no circumstances can it be used or considered as an offer to sell or as a solicitation of any offer to buy or sell the securities mentioned within it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which PCIL believe is reliable. PhillipCapital (India) Pvt. Ltd. or any of its group/associate/affiliate companies do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice.

Important: These disclosures and disclaimers must be read in conjunction with the research report of which it forms part. Receipt and use of the research report is subject to all aspects of these disclosures and disclaimers. Additional information about the issuers and securities discussed in this research report is available on request.

S (TP 4500)

B (TP 5430)

S (TP 5900) S (TP 6000) B (TP 7700)

B (TP 8400) B (TP 8400)

B (TP 10200)

N (TP 10875)

B (TP 12000)

B (TP 12000)

2000

3000

4000

5000

6000

7000

8000

9000

10000

11000

12000

13000

D-15 F-16M-16M-16 J-16 A-16 S-16 O-16D-16 J-17 M-17A-17 J-17 J-17 S-17 O-17N-17 J-18 F-18 A-18M-18 J-18 A-18O-18N-18 J-19



Certifications: The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst’s personal views about all of the subject issuers and/or securities, that the analyst(s) have no known conflict of interest and no part of the research analyst’s compensation was, is, or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

Additional Disclosures of Interest: Unless specifically mentioned in Point No. 9 below: 1. The Research Analyst(s), PCIL, or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in

this report. 2. The Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively do not hold more than 1% of the securities of the

company (ies)covered in this report as of the end of the month immediately preceding the distribution of the research report. 3. The Research Analyst, his/her associate, his/her relative, and PCIL, do not have any other material conflict of interest at the time of publication of this

research report. 4. The Research Analyst, PCIL, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for

any other products or services from the company(ies) covered in this report, in the past twelve months. 5. The Research Analyst, PCIL or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for

the company (ies) covered in this report. 6. PCIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in

connection with the research report. 7. The Research Analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report. 8. The Research Analyst and PCIL has not been engaged in market making activity for the company(ies) covered in the Research report. 9. Details of PCIL, Research Analyst and its associates pertaining to the companies covered in the Research report:

Sr. no. Particulars Yes/No

1 Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by PCIL

No

2 Whether Research Analyst, PCIL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1% of the company(ies) covered in the Research report

No

3 Whether compensation has been received by PCIL or its associates from the company(ies) covered in the Research report No

4 PCIL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report

No

5 Research Analyst, his associate, PCIL or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months

No

Independence: PhillipCapital (India) Pvt. Ltd. has not had an investment banking relationship with, and has not received any compensation for investment banking services from, the subject issuers in the past twelve (12) months, and PhillipCapital (India) Pvt. Ltd does not anticipate receiving or intend to seek compensation for investment banking services from the subject issuers in the next three (3) months. PhillipCapital (India) Pvt. Ltd is not a market maker in the securities mentioned in this research report, although it, or its affiliates/employees, may have positions in, purchase or sell, or be materially interested in any of the securities covered in the report.

Suitability and Risks: This research report is for informational purposes only and is not tailored to the specific investment objectives, financial situation or particular requirements of any individual recipient hereof. Certain securities may give rise to substantial risks and may not be suitable for certain investors. Each investor must make its own determination as to the appropriateness of any securities referred to in this research report based upon the legal, tax and accounting considerations applicable to such investor and its own investment objectives or strategy, its financial situation and its investing experience. The value of any security may be positively or adversely affected by changes in foreign exchange or interest rates, as well as by other financial, economic, or political factors. Past performance is not necessarily indicative of future performance or results.

Sources, Completeness and Accuracy: The material herein is based upon information obtained from sources that PCIPL and the research analyst believe to be reliable, but neither PCIPL nor the research analyst represents or guarantees that the information contained herein is accurate or complete and it should not be relied upon as such. Opinions expressed herein are current opinions as of the date appearing on this material, and are subject to change without notice. Furthermore, PCIPL is under no obligation to update or keep the information current. Without limiting any of the foregoing, in no event shall PCIL, any of its affiliates/employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this document.

Copyright: The copyright in this research report belongs exclusively to PCIPL. All rights are reserved. Any unauthorised use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the PCIPL’s prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

Caution: Risk of loss in trading/investment can be substantial and even more than the amount / margin given by you. Investment in securities market are subject to market risks, you are requested to read all the related documents carefully before investing. You should carefully consider whether trading/investment is appropriate for you in light of your experience, objectives, financial resources and other relevant circumstances. PhillipCapital and any of its employees, directors, associates, group entities, or affiliates shall not be liable for losses, if any, incurred by you. You are further cautioned that trading/investments in financial markets are subject to market risks and are advised to seek independent third party trading/investment advice outside PhillipCapital/group/associates/affiliates/directors/employees before and during your trading/investment. There is no guarantee/assurance as to returns or profits or capital protection or appreciation. PhillipCapital and any of its employees, directors, associates, and/or employees, directors, associates of PhillipCapital’s group entities or affiliates is not inducing you for trading/investing in the financial market(s). Trading/Investment decision is your sole responsibility. You must also read the Risk Disclosure Document and Do’s and Don’ts before investing.

Kindly note that past performance is not necessarily a guide to future performance.

For Detailed Disclaimer: Please visit our website www.phillipcapital.in IMPORTANT DISCLOSURES FOR U.S. PERSONS This research report is a product of PhillipCapital (India) Pvt. Ltd. which is the employer of the research analyst(s) who has prepared the research report. PhillipCapital (India) Pvt Ltd. is authorized to engage in securities activities in India. PHILLIPCAP is not a registered broker-dealer in the United States and,

http://www.phillipcapital.in/



therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to “major U.S. institutional investors” in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not a Major Institutional Investor.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Rosenblatt Securities Inc, 40 Wall Street 59th Floor, New York NY 10005, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through PHILLIPCAP. Rosenblatt Securities Inc. accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority (“FINRA”) and may not be an associated person of Rosenblatt Securities Inc. and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account. Ownership and Material Conflicts of Interest Rosenblatt Securities Inc. or its affiliates does not ‘beneficially own,’ as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Rosenblatt Securities Inc, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Rosenblatt Securities Inc. is not aware of any material conflict of interest as of the date of this publication Compensation and Investment Banking Activities Rosenblatt Securities Inc. or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months. Additional Disclosures This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither PHILLIPCAP nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report’s preparation or publication, or any losses or damages which may arise from the use of this research report.

PHILLIPCAP may rely on information barriers, such as “Chinese Walls” to control the flow of information within the areas, units, divisions, groups, or affiliates of PHILLIPCAP.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by PHILLIPCAP with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of PHILLIPCAP and PHILLIPCAP accepts no liability whatsoever for the actions of third parties in this respect.

PhillipCapital (India) Pvt. Ltd. Registered office: 18th floor, Urmi Estate, Ganpatrao Kadam Marg, Lower Parel (West), Mumbai – 400013, India.

institutional equity research nestle india (nest in...

Documents